News Headlines
-
Suvoda And Greenphire Announce Completion of Merger
7/9/2025
Suvoda and Greenphire have announced the successful completion of their previously announced merger. Through this merger, the combined company is now better equipped to provide a comprehensive solution to its customers to support the urgent and mission critical moments of their clinical trials.
-
Novotech Showcased In Global Biotech Series For Innovation In Hepatitis B Research
7/8/2025
Novotech a globally recognized full-service clinical research organization (CRO) and scientific advisory company, is featured in The Next Frontier, a global branded series presented by the Biotechnology Innovation Organization (BIO) and produced by BBC StoryWorks Commercial Productions.
-
ActiGraph Is Rebranding As Ametris
7/7/2025
ActiGraph has rebranded to Ametris to reflect its expanded data and technology platform, marking a new chapter in data-driven drug development and digital evidence generation.
-
Cutting-Edge Innovation Steals Spotlight On London Biotechnology Show 2025 Exhibition Floor
6/27/2025
The London Biotechnology Show 2025 exhibition floor was a vibrant epicentre of innovation, featuring nearly 100 exhibiting companies representing the entire biotechnology value chain—from laboratory equipment and health tech to compliance and logistics.
-
Nanoform Starts Pivotal Human Bioequivalence Studies Of Nanoenzalutamide
6/12/2025
Nanoform Finland Plc, the medicine performance-enhancing company, today announced that it had started pivotal relative bioequivalence studies of Nanoenzalutamide, the nanocrystalline-enabled enzalutamide tablet formulation, a potential alternative to the amorphous solid dispersion (ASD) used in XTANDI® (enzalutamide) [1], the number one prescribed androgen receptor inhibitor [2] approved to treat prostate cancer.
-
Australia Delivers Certainty For US Biotechs In 2025: Avance Clinical Offers Fast Start-Up, Regulatory Predictability, And R&D Rebates
5/28/2025
As regulatory uncertainty grows in the United States, US biotechs are increasingly looking to Australia as a stable and predictable launchpad for early-phase clinical trials. With its globally accepted regulatory framework, accelerated timelines, and 43.5% R&D rebate, Australia offers a compelling advantage — and Avance Clinical, Australia’s leading early-phase specialist CRO, is delivering the GlobalReady solution to help biotechs de-risk, conserve capital and accelerate their programs.
-
Reduce Complexity For Oncology Sites, Sponsors, Patients, And Caregivers
5/27/2025
Medable Inc. announced its next-generation digital oncology trial offering specifically designed to reduce operational complexity for sites and sponsors.
-
Meet With Avance Clinical At ASCO 2025 In Chicago
5/20/2025
Avance Clinical will attend and host a booth at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled from May 30 to June 3, 2025, at McCormick Place in Chicago, Illinois. This premier event brings together oncology professionals from around the world to connect, collaborate, and inspire advancements in cancer care.
-
Avance Clinical Honored With Frost & Sullivan's 2025 Global Customer Value Leadership Award
5/20/2025
Frost & Sullivan has named Avance Clinical the recipient of its 2025 Global Customer Value Leadership Award in the biotech contract research organization (CRO) sector, highlighting the company’s outstanding performance in delivering exceptional client value through innovation, service excellence, and technology-enabled trial optimization.
-
Novotech Welcomes New Investment From GIC, Temasek, And Existing Investor TPG To Accelerate Global Growth
5/14/2025
Novotech, a globally recognized full-service biotech specialist clinical research organization (CRO), announced today that affiliates of GIC and Temasek have signed binding agreements to acquire a significant stake in the company, with the additional capital earmarked to accelerate its global growth. Existing investor TPG will also reinvest through its TPG Asia fund.